Turnover
≈ €140,000 estimated
The micro format states no turnover.
AMLES
Lifetime
2 annual accounts with figures on one time axispeak €46,898 (2025)
€46,898▲ 16.0%
peak €33,449 (2025)
€33,449▲ 17.2%
peak €66,985 (2025)
€66,985▲ 99.7%
€6,502▼ 29.1%
Board1 name since 2023
1 director
Documentsfilings and deeds
20-06-202641 days before the deadline
2025micro format
Gross margin from €40,421 to €46,898Equity from €33,536 to €66,985Debts from €9,174 to €6,502Cash from €21,468 to €40,036
Key points
from the 2025 annual accountsLiquidity
11.30 was 4.66 in 2024
Short-term debts fell from €9,174 to €6,502.
Position in the sector
91.2%
Higher solvency than 85% of companies in human health. Sector median 63.0% · 21,311 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,274 companies had the same profile as AMLES has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,274 companies, not a prediction for AMLES. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1002764620
Registered office moved from Waimes to Stavelot
New registered office: Route de Cronchamps 80- 4970 STAVELOT · Previous registered office: Vole de Remonval 17-4950 WAIMES · Board meeting of 01-07-2024 · Gazette deed
Incorporation
Founding capital of €5,000, 100 shares · Founder: · Appointment: (director) · published on 30-11-2023 · Gazette deed
First establishment
Voie de Remonval,Ondenval 17, Waimes
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| AMLES Stavelot | €73,487 | €46,898 | 91.2% | - |
| Docteur Florence ROBERT Welkenraedt | €85,874 | €46,871 | 59.5% | - |
| Docteur Anne Van Eyken Ixelles | €74,332 | €47,095 | 90.4% | - |
| Sarama Leuven | €71,614 | €45,956 | 74.8% | - |
| Health Expert Partner Jodoigne | €79,607 | €47,421 | 94.3% | - |
| Docteur Mavrick Dufrasne Woluwe-Saint-Lambert | €75,539 | €46,379 | 74.3% | - |
| Dr Alizée Detiffe Chastre | €79,287 | €48,601 | 60.8% | - |
These companies have the same main activity as AMLES: general medical practice (NACE 86210). They are comparable in size and age: total assets between €71,600 and €85,900, founded between 2023 and 2024.
Official details
Source: KBO- Status
- Active since 28-11-2023Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment unit
- 2.352.333.5384950 Waimes, since 28-11-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 27-11-2025
Annual accounts 2025
- €73,487▲ 72.1%
- Filing
- Filed on 20-06-2026, 41 days before the end of the filing period
Insights on AMLES
AMLES has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €66,985 and a net result of €33,449.
Its solvency ranks better than 85% of 21,311 sector peers (NACE 86, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about AMLES
- What is the company number of AMLES?
- The company number of AMLES is 1002.764.620. The VAT number is the same number with BE in front: BE 1002.764.620.
- Where is AMLES based?
- The registered office is at Route du Cronchamps 80, 4970 Stavelot.Company details
- What does AMLES do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of AMLES?
- AMLES is a private limited company (BV).
- When was AMLES founded?
- AMLES was founded on 28-11-2023.
- Is AMLES still active?
- Yes, AMLES is an active enterprise in the KBO register.
- What is the turnover of AMLES?
- The turnover in financial year 2025 is ≈ €140,000. This figure is estimated from the gross margin of €46,898 and 47 comparable companies (NACE 86). It probably lies between €100,000 and €200,000.Financials
- Is AMLES profitable?
- In financial year 2025, AMLES made a profit of €33,449.
- Where can I find the annual accounts of AMLES?
- AMLES filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of AMLES due?
- AMLES must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.